Evaluation of the Clinical Utility of Renin‐Angiotensin System Inhibitors in Patients Undergoing Radical Surgery for Urothelial Carcinoma of the Upper Urinary Tract

[1]  T. Matsuda,et al.  Preoperative Pyuria Is a Poor Prognostic Factor in Patients With Urothelial Carcinoma of the Upper Urinary Tract After Surgery , 2017, Clinical genitourinary cancer.

[2]  Steven L. Chang,et al.  Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Choi,et al.  The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[4]  T. Matsuda,et al.  Prognostic Impact of Renin-Angiotensin Inhibitors in Patients with Bladder Cancer Undergoing Radical Cystectomy , 2017, Annals of Surgical Oncology.

[5]  M. Blute,et al.  Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. , 2015, The Journal of urology.

[6]  Biao Wang,et al.  Angiotensin II type 1 receptor-associated protein plays a role in regulating the local renin-angiotensin system in HSC-T6 cells. , 2015, Molecular medicine reports.

[7]  E. Kikuchi,et al.  Renin–angiotensin system blockade: Its contribution and controversy , 2015, International journal of urology : official journal of the Japanese Urological Association.

[8]  J. Chin,et al.  Targeting the VEGF pathway in metastatic bladder cancer , 2015, Expert opinion on investigational drugs.

[9]  M. Babjuk,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. , 2015, European urology.

[10]  N. Frangogiannis,et al.  Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. , 2014, Translational research : the journal of laboratory and clinical medicine.

[11]  E. Kikuchi,et al.  Prognostic Value of Renin–Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer , 2012, Annals of Surgical Oncology.

[12]  V. Margulis,et al.  Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. , 2012, European urology.

[13]  E. Kikuchi,et al.  Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma , 2011, British Journal of Cancer.

[14]  E. Kikuchi,et al.  Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer , 2011, British Journal of Cancer.

[15]  E. Kikuchi,et al.  Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. , 2011, Urology.

[16]  E. Kikuchi,et al.  Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer , 2007, Human Cell.

[17]  Songbin Fu,et al.  Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF‐7 breast cancer cells survival via PI3‐kinase/Akt pathway , 2010, Journal of cellular physiology.

[18]  A. Leask.  Potential Therapeutic Targets for Cardiac Fibrosis: TGF&bgr;, Angiotensin, Endothelin, CCN2, and PDGF, Partners in Fibroblast Activation , 2010, Circulation research.

[19]  A. Finelli,et al.  Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. , 2009, Urology.

[20]  E. Kikuchi,et al.  Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer. , 2009, Reviews on recent clinical trials.

[21]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[22]  Jaclyn H Neo,et al.  Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases , 2007, Journal of gastroenterology and hepatology.

[23]  E. Kikuchi,et al.  Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer , 2006, Clinical Cancer Research.

[24]  K. Sharma,et al.  Transforming growth factor-beta: A clinical target for the treatment of diabetic nephropathy , 2004, Current diabetes reports.

[25]  L. Murray,et al.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.